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Generally, clinical parameters are used in dental practice for periodontal disease, yet
several drawbacks exist with the clinical standards for addressing the needs of the
public at large in determining the current status/progression of the disease, and requiring
a significant amount of damage before these parameters can document disease.
Therefore, a quick, easy and reliable method of assessing and monitoring periodontal
disease should provide important diagnostic information that improves and speeds
treatment decisions and moves the field closer to individualized point-of-care diagnostics.
Objective: This report provides results for a saliva-based diagnostic approach
for periodontal health and disease based upon the abundance of salivary analytes
coincident with disease, and the significant progress already made in the identification of
discriminatory salivary biomarkers of periodontitis.
Methods: We evaluated biomarkers representing various phases of periodontitis
initiation and progression (IL-1ß, IL-6, MMP-8, MIP-1α) in whole saliva from 209 subjects
categorized with periodontal health, gingivitis, and periodontitis.
Results: Evaluation of the salivary analytes demonstrated utility for individual biomarkers
to differentiate periodontitis from health. Inclusion of gingivitis patients into the analyses
provided a more robust basis to estimate the value of each of these analytes. Various
clinical and statistical approaches showed that pairs or panels of the analytes were able
to increase the sensitivity and specificity for the identification of disease.
Conclusions: Salivary concentrations of IL-1ß, IL-6, MMP-8, MIP-1α alone and in
combination are able to distinguish health from gingivitis and periodontitis. The data
clearly demonstrated a heterogeneity in response profiles of these analytes that supports
the need for refinement of the standard clinical classifications if we are to move toward
precision/personalized dentistry for the twenty-first century.
Keywords: periodontitis, saliva, MMP-8, cytokines, personalized medicine
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Introduction

1993; Fine et al., 2009; Giannobile et al., 2009; Miller et al.,
2010; Kinney et al., 2011; Shaila et al., 2013; Prakasam and
Srinivasan, 2014) Consistent with this, recent data from our lab
and others indicate that salivary concentrations of IL-6, IL-8,
albumin, calprotectin, PGE2 , MMP-8, and MIP-1α are elevated in
patients who have gingivitis (Lee et al., 2012; Syndergaard et al.,
2014).
Use of salivary biomarkers in conjunction with the expanded
panel of potential biomarkers from recent investigations using
proteomic and transcriptomic analyses could help dentistry move
toward the era of personalized medicine. However, advances
will require studies that analyze biospecimens and compare
biomarkers from patients exhibiting the full spectrum of disease
(health, gingivitis, and periodontitis), as studies regarding this
spectrum of disease have been lacking. This report addresses this
gap and describes an approach that reflects Phase I standards
that are articulated regarding the discovery, validation, and utility
assessment of biomarkers for disease detection (Pepe et al., 2001).
Periodontal disease is a chronic inflammatory and destructive
condition that affects an estimated 80% of U.S. adults that
can have significant systemic consequences. Customary clinical
parameters are used in dental practice because of their ease
of use, relative non-invasiveness and reliability. Yet several
drawbacks exist with the current standards for addressing the
needs of the public at large. First, a highly trained clinician and
assistant are needed to record the findings. Second, collection
of this diagnostic information includes the use of expensive
radiographic equipment that makes the procedure time and
labor intensive, as well as imposing significant financial costs
to the consumer. Third, even in the hands of experts, several
of these readings are somewhat subjective by the evaluator and
tend to vary in accuracy not only from one evaluator to the
next, but by the best of examiners. Equally important is the
fact that these clinical parameters cannot determine current
status of the disease, and a significant amount of damage must
occur before these diagnostic parameters are able to detect a
sufficient level of disease. Our hypothesis was that a combination
of salivary analytes that relate to the biological processes of
periodontitis will effectively discriminate this destructive disease
from gingival inflammation and periodontal health. Therefore,
the possibility of a quick, easy and reliable method of assessing
and monitoring periodontal disease should provide important
diagnostic information that improves and speeds treatment
decisions and moves the field closer to individualized point-ofcare diagnostics.

Historically, the health of the periodontium has been defined by
clinical parameters that describe a lack of gingival inflammation
bleeding on probing (BOP), changes in the epithelial barrier
relationship to the cementoenamel junction clinical attachment
level (CAL), and loss of underlying alveolar bone architecture
probing pocket depth (PPD) (Armitage and Robertson, 2009;
Armitage and Cullinan, 2010). However, coincident with
these macro-clinical measures, histological studies have clearly
identified some local tissue inflammatory response to the
juxtaposed supra- and subgingival microbial ecology, even in
“clinically healthy” sites (Page and Schroeder, 1976; Armitage
et al., 1977; Brecx et al., 1986). This type of mucosal “physiologic
inflammation” has also been described in gastrointestinal
mucosal tissues and is considered important in the normal
host-bacterial interactions to maintain tissue homeostasis (Silva
et al., 2007; Rabinowitz and Mayer, 2012). These histological
findings of the periodontium are coincident with data describing
detectable levels of a select group of host response molecules
in healthy tissues, that are generally considered to increase
significantly in magnitude and expand in an array of responses
with gingivitis (Offenbacher et al., 2009, 2010; Jönsson et al.,
2011; Leishman et al., 2013) and periodontitis (Kim et al., 2006;
Beikler et al., 2008; Kebschull et al., 2013, 2014). However, these
findings have not been effectively extrapolated into creating
a paradigm that integrates biological and clinical measures of
health of the gingival tissues as an important, and potentially
crucial, biomedical informatics approaches for assessing disease
presence, prognosis, and progression.
Gingivitis is an often-overlooked disease, despite being the
“Gateway” to periodontitis for a significant portion of the
population (Page, 1986; Albandar et al., 1998; Schätzle et al.,
2003, 2004, 2009; Lang et al., 2009). This issue has persisted
for years, in part because clinical parameters along with predefined thresholds of inflammation and measurable tissue
destruction have been used as the “gold standard” for discerning
health/gingivitis from periodontitis. While very helpful, they
neither provide insights into patient-specific variations within
these inexact disease groups, nor do they help predict nonresponders and those who “at risk” for disease progression. Thus,
novel methods for identifying those “at risk persons” are needed.
Differential host responses are thought to contribute to
various susceptibilities that play an important role in determining
progression of the inflammatory lesion (Kornman et al., 1997;
Trombelli, 2004; Van Dyke and Sheilesh, 2005; Grigoriadou et al.,
2010; Ebersole et al., 2013). At the cellular level, exposure to
bacterial products and lipopolysaccharide (LPS) elicit activation
of monocytes/macrophages that promote secretion of cytokines
and inflammatory mediators such as IL-1β, IL-6, and TNFα that
results in the release of matrix metalloproteinases (MMPs) that
undermine the integrity of the gingival tissues (Yucel-Lindberg
and Båge, 2013). Many of these inflammatory molecules have
been detected in oral fluids (Sorsa et al., 1999; Miller et al., 2006),
which has allowed saliva to emerge as an important and easily
accessible biological fluid that can provide important diagnostic
information regarding oral health and disease (Henskens et al.,
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Materials and Methods
These case-control studies were conducted at the University of
Kentucky College of Dentistry from 2009 through 2013. The
protocols were approved by the Institutional Review Board at the
University of Kentucky (12-0673-F2L; 04-0339-F1V; 10-0615F6A; 07-0780-F6A). Participants were recruited from the general
clinic and student populations of the College of Dentistry. Two
hundred and nine persons participated some of whom have been
described in previous reports (Thomas et al., 2009; Al-Sabbagh
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et al., 2012; Syndergaard et al., 2014). Each participant was given
verbal and written information that described the nature of the
study, and each signed informed consent prior to enrollment
of the study. Inclusion criteria included subjects older than 18
years of age who were in good general health (excluding the case
definition) and had a minimum of 20 teeth.
Individuals were excluded from either group if there
was evidence of alcoholism, liver, kidney, or salivary gland
dysfunction, inflammatory bowel disease, granulomatous
diseases, diabetes, undergoing or had undergone organ transplant
or cancer therapy, had a periodontal abscess or had previous
treatment for periodontal disease or aggressive periodontitis.
Pregnancy or lactation, use of antibiotics or immunosuppressant
medication within the last 1 month, need for antibiotics for
infective endocarditis prophylaxis during dental procedures,
symptoms of acute illness (i.e., fever, sore throat, body aches, and
diarrhea), removable prosthodontic or orthodontic appliances
or presence of an oral mucosal inflammatory condition (e.g.,
aphthous, lichen planus, leukoplakia, and oral cancer) also were
exclusion criteria.

The MILLIPLEX MAP Kit (EMD Millipore, Billerica, MA, USA)
was used to detect IL-1β, IL-6, MMP-8, and MIP-1α. This kit was
used to analyze individual saliva samples for the four analytes
using a Luminex 100IS instrument (EMD Millipore) according
to the manufacturer’s instructions. All analyses were performed
in duplicate within 6 months of obtaining the sample. Standards
were included on all runs, and all results are reported within the
linearity of the assays.

Statistical Analyses
Descriptive statistics were calculated for the demographic data
and individual salivary anaytes. An ANOVA was used to evaluate
differences in levels across the three groups with Tukey’s posthoc testing (SigmaStat v3.5, San Jose, CA). A Pearson Correlation
analysis was conducted to relate levels of the salivary analytes to
clinical features of the population. Finally, Chi-square test and
Relative Risk ratio was determined using individual analytes to
discriminate periodontitis from health or gingivitis (MedCalc,
v14.12, Ostend, Belgium).
To determine the optimal cut points for distinguishing
between the periodontitis and non-periodontitis patients
(healthy and gingivitis) the analytes were used individually as
predictors in a linear regression model (SAS v9.4, Cary, NC).
The intersection of the sensitivity and specificity was used as
the optimal cut point for the predictors. The AUC was also
calculated for each individual analyte.
Four different classification techniques namely [Linear
Discriminant Analysis (LDA), Quadratic Discriminant Analysis
(QDA), Naïve Bayes Classifier (NB), Support Vector Machine
(SVM)] were used to discern gingivitis from periodontitis
and health from periodontitis using the salivary markers.
Classification performance measures (sensitivity, specificity and
accuracy) were estimated using the clinical labels of the samples
as the ground truth and leave-ten-out cross-validation where
10 samples are set aside as the test set with the remaining
samples as the training set. The mean values of the classification
performance measures were estimated across (N = 100)
independent realizations by randomly assigning the samples to
the test and training sets. Classification was repeated using all
possible combinations of markers (pairs, triplets, and all four
markers).

Clinical Evaluation
All subjects received a full mouth periodontal examination. The
medical and dental history was obtained and reviewed along with
exclusion criteria prior to the periodontal examination. Findings
from the head, neck, and oral examination were recorded as being
normal or abnormal. All clinical findings were recorded on data
collection worksheets. PPD was measured at six locations per
tooth (mesial-buccal, mid-buccal, distal-buccal, mesial lingual,
mid-lingual, and distal-lingual) using a PCP-UNC 15 probe.
After the measurement of PPDs, all sites were observed for BOP
(Thomas et al., 2009; Sexton et al., 2011; Al-Sabbagh et al., 2012;
Syndergaard et al., 2014). CAL was also determined at all six
locations per tooth. The percentage of sites affected with BOP
and PPD were calculated by taking the number of sites affected
divided by the total number of sites present for each subject.
Healthy patients were categorized by BOP at ≤10% of sites (6
sites per tooth), <3% of sites with PPD ≥ 4 mm, and no sites with
clinical attachment loss (CAL) ≥ 2 mm. Subjects in the gingivitis
group were defined as BOP at ≥20% of sites, <3% of sites with
PPD ≥ 4 mm, and no sites with CAL ≥ 2 mm. The periodontitis
group had BOP at >10% of sites, with >5% of sites with PPD ≥
4 mm and CAL ≥ 2 mm.

Results

Salivary Samples

Distribution of Analytes in Saliva

Saliva samples were collected from both groups prior to clinical
evaluation. All subjects rinsed with tap water (10 mL) for 30 s
and expectorated prior to saliva collection. Unstimulated whole
saliva was collected according to a modification of the method
described by Navazesh (1993). Subjects were asked to avoid oral
hygiene measures (i.e., flossing, brushing, and mouth rinses),
eating, drinking, or gum chewing 1 h prior to saliva collection.
Subjects then expectorated at least 5 mL of unstimulated whole
saliva into sterile tubes containing lyophilized protease inhibitor
solution (SIGMAFast). Saliva samples were collected on ice.
Aliquots were prepared and samples were frozen at -80◦ C until
analysis.

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org

Included in the cohort were 65 subjects in the healthy group,
43 subjects in the gingivitis group and 101 subjects in the
periodontitis group, with some differences in age, gender,
race/ethnicity, and smoking across the groups (Table 1).
The profiles of salivary analytes IL-1ß, IL-6, MMP-8, and MIP1α in the cohort are displayed in Figure 1. IL-1β concentrations
were significantly higher in the periodontitis group (102.3 ± 10.1
SEM pg/mL) compared to levels in the gingivitis (28.7 ± 7.3) and
healthy (14.6 ± 2.6) subjects. A minimal difference was noted in
the cytokine comparing the overall gingivitis group to the healthy
individuals. Similarly, a significantly elevated concentration of
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Based upon these threshold values, the results in Table 3 show
that for elevated concentrations of IL-1ß, IL-6, and MMP-8
significantly categorized periodontitis patients compared with
both healthy and gingivitis groups. These data also provided
an assessment of the relative risk for a patient to be clinically
classified as periodontitis based upon the individual biomarkers,
with each marker showing a very high level of significance and
a 2 to 4-fold relative risk when the concentration was above the
threshold.
We developed ROC curves and determined the AUC (cstatistic) for each analyte individually (Figure 3) by comparing
the levels in the periodontitis group vs. those identified in both
health and gingivitis. The summary results in Table 4 show the
highest sensitivity and specificity for periodontitis with both
IL-1ß and IL-6, paralleling the results found using our earlier
approaches to stratify the analyte levels with disease.
Finally, in recognizing the capacity of ROC analyses to
potentially overfit the classification properties of the data (Baker,
2003), we utilized four classification techniques (LDA, QDA, NB,
SVM) to evaluate the capacity of various groupings of analytes to
effectively categorize the periodontitis patients. Table 5 provides
the classification performance measures (sensitivity, specificity,
accuracy) using the LDA approach. Outcomes from QDA, NB,
and SVM were similar hence not shown. The LDA results
were consistent with the ROC analyses and clearly showed
that combinations of these biomarkers improved the sensitivity,
specificity, and accuracy of the identification of periodontitis
vs. either health or gingivitis subjects when compared to the
performance of the individual biomarkers. As might be expected,
the greatest sensitivity, specificity, and accuracy were identified in
comparing health with periodontitis patients. The classification
performance measures using the pair (IL-1ß, IL-6) was especially
pronounced indicating that these molecular markers play a
critical role in discerning periodontitis from gingivitis and health.

TABLE 1 | Demographics of the population.
Healthy
(n = 65)

Gingivitis
(n = 43)

Periodontitis
(n = 101)

28.2 ± 5.9a

27.8 ± 4.5a

42.0 ± 10.4a

Female (%)

60.0a

48.8a

32.7a

White (%)

90.0a

95.4a

41.60a

2.5

2.3

34.7

0

2.3

17.8

Asian/Other (%)

7.5

0

6.9

Current tobacco use (%)

0a

0a

28.0a

27.6
(range 20–32)

27.6
(range 24–28)

27.1
(range 20–28)

Age (years; mean ± SD)

Hispanic (%)
African American (%)

No. of teeth

PERIODONTAL INDICES (%SITES; MEAN ± SD)
4.26 ± 3.4a,b

25.4 ± 5.9a,b

57.4 ± 24.2a

PD ≥ 4 mm sites

0.6 ± 1.1a

0.6 ± 2.0a

27.3 ± 14.7a

PD ≥ 5 mm sites

0.1 ± 0.3a

0.1 ± 0.2a

16.6 ± 11.2a

BOP sites

a Significantly
b Significantly

different from periodontitis group at least at p < 0.05.
different from healthy group at least at p < 0.05.

salivary IL-6 was found in the periodontitis group (22.8 ±
3.7 pg/mL) compared to both the gingivitis (6.3 ± 2.7) and
healthy (3.7 ± 0.5) subjects. Consistent with this, IL-6 levels
were below the level of detection in the assay (0.64 pg/mL) in
approximately 2% of the periodontitis patients, compared with
nearly 20% of both gingivitis and healthy subjects. MMP-8 levels
were also significantly elevated in the periodontitis group (314.1
± 25.5 ng/mL) compared to both gingivitis (199.0 ± 29.1) and
healthy (130.7 ± 14.5) subjects, although there appeared to be a
greater overlap across the groups with this analytes vs. the others
that were examined. Finally, MIP-1α was significantly increased
in the periodontitis group (16.2 ± 2.2 pg/mL) compared to both
gingivitis (12.0 ± 2.2) and health (3.2 ± 1.0) groups.

Salivary Analytes and Disease Measures

Discussion

The relationship of these salivary biomarkers with the clinical
parameters of oral disease was examined in an attempt to identify
any clinical and biological relationships. Across the spectrum
of patents, IL-1ß, IL-6, and MMP-8 levels were significantly
positively correlated with BOP frequency in the population, while
both IL-1ß and MMP-8 were significantly correlated with percent
sites with advanced PPDs across the population (Figure 2).
Table 2 shows the results describing that only IL-1ß and MMP8 levels were significantly correlated with PPD levels across the
population and that this relationship was also observed in the
periodontitis patients to a similar degree with the extent of
disease (i.e., %sites with ≥4 mm or ≥5 mm PPD) and the severity
of disease (i.e., mouth mean PPD).

Studies over the last two decades have provided an array of
targets for detection of various substances in saliva (Desai and
Mathews, 2014), including drugs of abuse (Moore and Crouch,
2013), alcohol (Swift, 2003), estradiol (Lewis, 2006), cotinine
(Scheidweiler et al., 2011), cortisol (van Andel et al., 2014), and
HIV antibody (Pant Pai et al., 2012) as examples. Based upon
the potential value of saliva as a non-invasive screening tool for
oral disease(s), this study focused on the quantification of a group
of analytes that may act as biomarkers for periodontitis and aid
in the development of personalized approaches for periodontal
risk assessment. Movement toward an era of personalized
medicine and individualized clinical decisions in periodontology
requires significant improvement in our ability to define risk and
predict disease progression. While the medical field routinely
makes clinical diagnoses based on signs and symptoms (e.g.,
pneumonia, diarrhea), decisions on patient management and
treatment do not stop here. Modern medicine integrates these
clinical descriptors with biological assessments that enable the
physician to focus on the specific disease etiology and unique
features of the patient in finalizing a treatment strategy. However,

Discriminatory Analytes and Periodontal Disease
Data were then used to explore the capacity of these four
analytes to effectively discriminate periodontitis from gingivitis
and health. Three strategies were used in this approach.
First threshold cutoff values for each analyte were based
upon the population distribution for IL-1ß (≥28 pg/mL), IL-6
(≥5.5 pg/mL), MMP-8 (≥140 ng/mL), and MIP-1α (≥5 pg/mL)
and selected to optimize sensitivity for detection of periodontitis.

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org
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the vertical blue dashed line denotes the threshold cutoff for each analyte
(IL-1ß ≥ 28 pg/mL; IL-6 ≥ 5.5 pg/mL; MMP-8 ≥ 140 ng/mL; MIP-1α ≥
5 pg/mL).

FIGURE 1 | Distribution of levels of IL-1ß (A), IL-6 (B), MMP-8 (C), and
MIP-1α (D) in the three groups of subjects. Each point denotes the
analyte value for a patient. The vertical red line denotes the group mean and

number of cell types, and can elicit bone resorptive processes
(Huang et al., 2001; Braun and Schett, 2012), MMP-8 a primary
collagenase effective on both types I and III collagen and released
by neutrophils that alters the integrity of soft tissues in the
periodontium (Salminen et al., 2014), and MIP-1α (also known
as CCL3), a chemokine macrophage inflammatory protein
that binds to CCR1, CCR4, and CCR5 receptors frequently
on the surface of immune cells, recruiting them into sites of
inflammation (Kabashima et al., 2001). This chemokine has
also been found to activate osteoclasts, particularly related to
bone resorption in multiple myeloma through these receptors
(Terpos et al., 2005). Importantly, many of these biomarkers
have been detected in saliva and correlate with periodontal
disease. While it is clear that these biomolecules contribute to the
inflammatory and tissue destructive processes of periodontitis,
a number of them have also been detected in serum associated
with chronic inflammation related to systemic diseases (Fain,
2006; Zakynthinos and Pappa, 2009; Wu et al., 2010; Cierny et al.,
2014). We have also evaluated some of these in saliva and while
they can be elevated to some degree with systemic inflammation
vs. control individuals, the levels of these analytes in saliva with
periodontitis are significantly increased compared to any of the
systemic conditions (Mirrielees et al., 2010; Miller et al., 2014).
Nevertheless, a clinical medical history should be taken into

it is clear the clinical measures alone do not provide sufficient
information to determine which patients will/won’t progress,
and what therapy should be provided to those at risk. Recent
investigations using proteomic and transcriptomic analyses have
dramatically expanded the potential panel of biomarkers for
gingivitis; however, generally these studies have been limited
to comparisons of gingivitis with health, or periodontitis with
health (Offenbacher et al., 2009; Jönsson et al., 2011). No studies
have been published that extrapolate from these reports analytes
in gingival tissues, crevicular fluid, or saliva that discriminate
gingivitis from periodontitis.
Periodontitis represents a persistent inflammatory response
to chronic biofilms inhabiting the subgingival crevice
(Hajishengallis, 2014; Nibali et al., 2014). The current paradigm
suggests that variations in the quantity and quality of the oral
microbial ecology at health, gingivitis, and periodontitis sites
results in a dysregulated inflammatory response that causes
release of a variety of host biomolecules that lead to the clinical
features of periodontitis. These biomolecules can represent the
various stages of progression of the destructive inflammatory
response, including IL-1ß as a proinflammatory cytokine that has
effects on coupling processes in bone biology (Nakashima and
Takayanagi, 2009; Braun and Schett, 2012), IL-6 as a pleiotropic
cytokine that communicates inflammatory signals with a

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org
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FIGURE 2 | Correlation analyses of biomarkers IL-1ß (A), MMP-8 (B), and IL-6 (C) significantly related to clinical indices of periodontitis. Each point
denotes a patient in the population (n = 209) and the line denotes the correlation trendline.
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account to minimize false-positive responses in periodontally
healthy subjects.
IL-1ß has been identified in gingival crevicular fluid (GCF;
Faizuddin et al., 2003; Kinney et al., 2014) and saliva (Miller
et al., 2006; Yoon et al., 2012; Salminen et al., 2014) in
elevated levels in numerous investigations of periodontitis. Some
of these studies have also shown that the levels are related
to disease extent/severity (Tobón-Arroyave et al., 2008) and
decrease with therapy (Sexton et al., 2011). Moreover, while it
is somewhat controversial at this time, data exist suggesting that
polymorphisms in this gene impose a risk for periodontitis (Lang
et al., 2000; Lee et al., 2012; Diehl et al., 2015). We have previously
identified elevated levels of IL-1ß in saliva from periodontitis
patients compared to orally healthy individuals (Miller et al.,
2006, 2014; Frodge et al., 2008), and have shown a relatively stable
level of this analyte in whole saliva of healthy subjects over time
(Thomas et al., 2009; Syndergaard et al., 2014). The findings in
this study extended these results by inclusion of gingivitis patients
and demonstrating significant elevation in periodontitis saliva
and positive correlations of salivary IL-1ß levels with BOP and

measures of pocket PPD. Determining a threshold for positive
response at ≥28 pg/mL showed a significant discriminatory
power in periodontitis for this analyte, with a RR = 4.2772
for periodontitis with elevated salivary IL-1ß. This finding is
consistent with previous results reported by us and others;
however, these reports generally compared periodontitis to oral
health (Miller et al., 2006; Gursoy et al., 2009; Kaushik et al., 2011;
Kinney et al., 2014; Salminen et al., 2014).
Increased IL-6 levels have also been found in GCF (Fujita
et al., 2012; Javed et al., 2012) and saliva (Costa et al., 2010;
Gümüs et al., 2014; Javed et al., 2014) from periodontitis patients
vs. health controls. A limited number of studies have also
identified increases in IL-6 in periodontitis tissues (Duarte et al.,
2012), although a meta-analysis by Song et al. (2013) suggested
genetic polymorphisms for this cytokine may be limited in
their relationship to periodontitis across various populations.
Treatment studies have also documented decreases in IL-6 in
GCF following non-surgical periodontal therapy (Kardesler et al.,
2011; de Lima Oliveira et al., 2012). The overall levels of this
cytokine were substantially lower than IL-1ß, and nearly 25%
of the healthy/gingivitis groups showed no detectable IL-6 in
saliva and only 2/101 periodontitis patients. As such, the levels
were significantly elevated in the periodontitis group. Minimal
correlations in IL-6 levels across the population were observed,
appearing only related to BOP levels. However, using a threshold
value of =5.5 pg/mL, showed a significant increase in positive
responses in the periodontitis patients with a highly significant
RR = 4.1703 for elevated salivary IL-6 levels commensurate with
periodontitis.
MMP-8, a major factor produced by neutrophils at sites of
inflammation has a robust literature demonstrating elevations
in GCF (Tervahartiala et al., 2000; Mäntylä et al., 2006; Kinney
et al., 2014) and saliva (Javed et al., 2014; Salminen et al., 2014) in
periodontitis. Sorsa et al. (1999) have demonstrated the value of
detection of elevations in this analyte for diagnosing periodontitis
and following therapeutic intervention for the disease (Kinane
et al., 2003; Sexton et al., 2011). We had confirmed these types
of findings in periodontitis and healthy groups (Miller et al.,
2006), but demonstrate in this study differences also between
periodontitis and gingivitis patients. Interesting aspects of the
distribution of MMP concentrations was the large range in
values detected in saliva from each of the groups, and that
the gingivitis group showed significantly higher levels than

TABLE 2 | Correlation of individual salivary biomarkers with bleeding on
probing and frequency of probing pocket depths in the population.
Clinical measure

Analyte

%BOP > 0

IL-1ß

Total

Health

Gingivitis

Periodontitis

0.6144

−0.0311

−0.0719

0.4669

%PPD ≥ 4 mm

0.6429

−0.1219

−0.0006

0.5167

%PPD ≥ 5 mm

0.5836

0.0356

0.2142

0.4068

Mean PPD

0.6009

0.0757

−0.1269

0.4596

0.3622

0.0156

−0.0936

0.2098

%PPD ≥ 4 mm

0.2887

0.0848

−0.0136

0.0611

%PPD ≥ 5 mm

0.3163

−0.0146

0.0835

0.1305

Mean PPD

0.3247

0.1312

0.3292

0.0861

0.4841

0.1657

0.2583

0.3827

%BOP > 0

%BOP > 0

IL−6

MMP−8

%PPD ≥ 4 mm

0.4502

−0.1248

−0.00794

0.3613

%PPD ≥ 5 mm

0.4590

−0.1182

−0.1395

0.3746

0.4629

0.0733

−0.0602

0.3862

0.3280

−0.0308

−0.1141

0.1641

Mean PPD
%BOP > 0

MIP−1α

%PPD ≥ 4 mm

0.2821

−0.1540

−0.0136

0.1179

%PPD ≥ 5 mm

0.2883

−0.0958

−0.0691

0.1449

Mean PPD

0.2942

−0.3365

0.1428

0.1130

Figures in bold denote significant correlation at least at p < 0.05. Total denotes all 3
subgroups comprising the entire cohort.

TABLE 3 | Discriminatory power of individual analytes using thresholds based on responses across the population.
Analyte

Healthy
(n = 65)

Gingivitis
(n = 43)

Periodontitis
(n = 101)

IL-1ß

9a

10

76

X 2 = 57.24
P < 0.0001

X 2 = 31.76
P < 0.0001

4.2772 (2.8013–6.5309)
P < 0.0001

IL-6

10

10

78

X 2 = 58.26
P < 0.0001

X 2 = 34.73
P < 0.0001

4.1703 (2.7689–6.2810)
P < 0.0001

MMP-8

22

18

72

X 2 = 21.07
P < 0.0001

X 2 = 9.92
P = 0.0016

1.9440 (1.4722–2.5583)
P < 0.001

MIP-1α

7

12

42

X 2 = 34.6
P < 0.0001

X 2 = 2.15
NS

2.3637 (1.4787–3.7785)
P = 0.0003

a Denotes

Periodontitis vs. health

Periodontitis vs. gingivitis

Relative risk

number of patient samples above the thresholds of: IL-1ß—28 pg/mL, IL-6—5.5 pg/mL, MMP-8—140 ng/mL, MIP-1α—5 pg/mL.
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FIGURE 3 | ROC analysis of individual salivary analytes in the entire population, comparing levels in periodontitis to those in “not periodontitis” (i.e.,
health and gingivitis).

and dose-dependent manner (Giuliani et al., 2004). MIP1α has been detected at higher salivary levels (50-fold) in a
longitudinal study of seven adolescents who had aggressive
periodontitis compared with controls (Fine et al., 2009), and
appeared to increase prediction of disease progression. We
had shown previously that MIP-1α was significantly higher
in periodontitis subjects compared to healthy individuals
and decreased following periodontal therapy (Sexton et al.,
2011; Al-Sabbagh et al., 2012). These findings suggested that
the salivary level of MIP-1α could have clinical utility as a
screening tool for moderate to severe periodontal disease.
However, as we noted its utility for discriminating between
intermediate levels of disease (gingivitis, mild periodontitis)
and health was indeterminant. This study expanded the target
population and identified additional critical features of this
salivary analyte. First, concentrations in periodontitis were
significantly increased compared to both health and gingivitis
groups. Second, correlation with the various clinical parameters
was observed with the entire population. Finally using a
threshold of ≥5 pg/mL demonstrated a significantly increased
frequency of being classified as periodontitis with an RR =
2.3637.
While each of these analytes appeared useful in discriminating
periodontitis from health and gingivitis, the combination of
sensitivity, specificity, and accuracy was improved by exploring
combinations of the biomarkers. Our data showed that
concentrations above a defined threshold for any three of the
biomarkers identified 67.3% of periodontitis, 18.6% of gingivitis,

TABLE 4 | Results from ROC logistic regression analysis of individual
salivary biomarker levels comparing periodontitis group to “not
periodontitis” (i.e., health and gingivitis) group.
Analyte

Optimal cut*

Sensitivity

Specificity

PPV

NPV

AUC

IL-1β

24.00 pg/mL

0.752

0.759

0.745

0.766

0.830

IL-6

5.11 pg/mL

0.780

0.787

0.772

0.794

0.849

MMP8

165.92 ng/mL

0.653

0.667

0.647

0.673

0.728

MIP-1α

3.28 pg/mL

0.663

0.676

0.657

0.682

0.723

*The optimal cut was selected based on the intersection of the specificity and sensitivity
plots.

healthy subjects. This was not totally unexpected due to the
inflammation in the gingivitis patients. This finding was also
supported by the significant positive correlation of MMP-8
levels with all of the clinical measures. Identifying a threshold
of ≥140 ng/mL demonstrated a significantly greater frequency of
positive responses in periodontitis with an RR = 1.9440.
Of the analytes targeted in this study, MIP-1α has a
least amount of information regarding its distribution in
periodontitis. MIP-1α (CCL3) is a member of the cysteinecysteine chemokine family which is secreted by macrophages,
neutrophils, basophils, dendritic cells, lymphocytes and
epithelial cells and mediates granulocyte migration and adhesion
(Kabashima et al., 2001, 2002; Glass et al., 2003). It is an upstream
signaling protein that stimulates monocytes and/or osteoclast
progenitor cells to become active osteoclasts in a RANK/RANKL
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TABLE 5 | Average Classification performance measures (Sensitivity, Specificity, Accuracy) estimated across all possible combinations of markers using
leave-10-out cross-validation and 100 independent realizations.
IL-1ß
IL-6

IL-1ß
MMP-8

IL-1ß
MIP-1α

IL-6
MMP-8

IL-6
MIP-1 α

MMP-8
MIP-1 α

IL-1ß
IL-6
MMP-8

IL-1ß
IL-6
MIP-1 α

IL-6
MMP-8
MIP-1 α

IL-1ß
IL-6
MMP-8
MIP-1 α

HEALTH vs. PERIODONTITIS
Sensitivity

0.8115

0.7798

0.7965

0.8103

0.7878

0.7010

0.7780

0.8055

0.7948

0.7868

Specificity

0.7718

0.7675

0.7520

0.7283

0.7720

0.7728

0.7708

0.7868

0.7430

0.7820

Accuracy

0.7916

0.7736

0.7743

0.7693

0.7799

0.7369

0.7744

0.7961

0.7689

0.7844

GINGIVITIS vs. PERIODONTITIS
Sensitivity

0.7755

0.7630

0.7545

0.7843

0.8073

0.6473

0.7653

0.7830

0.7260

0.7803

Specificity

0.7565

0.7323

0.7865

0.7115

0.7073

0.6190

0.7538

0.7905

0.7340

0.7810

Accuracy

0.7660

0.7476

0.7705

0.7479

0.7573

0.6331

0.7595

0.7868

0.7300

0.7806

elevated levels of one or more of these salivary analytes.
Generally, when these elevated responses occurred, there were
multiple analyte elevations in the same individuals. Historically,
evaluation of salivary biomarker data was structured to “force”
the patients into a specific clinical group and accept that
this “within group heterogeneity” would be reflected in the
variation in analyte levels contributing to group differences.
However, in this era of personalized and precision medicine
(Hood et al., 2012; Mirnezami et al., 2012; Flores et al.,
2013; Schmidt, 2014), we submit that there is substantive
value in identifying these subsets of individuals within the
larger clinical groupings and document unique features of their
disease trajectory and/or patient specific responses that could
characterize risk or resistance to disease, and/or response to
therapy.

and 6.2% of healthy subjects. We then identified that pairs of
markers, including IL-1ß/IL-6, IL-1ß/MMP-8, and IL-6/MMP8, provided an increase in diagnostic ability by demonstrating
sensitivity and specificity values approximating 0.8. We also
identified that inclusion of three biomarkers into the biologic
diagnostic model, IL-1ß/IL-6/MMP-8, yielded a small increase
in the sensitivity, specificity, and accuracy values. Using MIP1α in these various groupings provided little improvement
in the discriminatory characteristics to identify periodontitis
patients. Finally, our diverse analyses allowed us to provide
potential thresholds to discriminate periodontitis (i.e., IL-1ß:
24–28 pg/mL; IL-6: 5.11–5.5 pg/mL; MIP-1α: 3.28–5 pg/mL, and
MMP-8: 140–165.9 ng/mL).
While these analytes have been evaluated as single biomarkers
in saliva for periodontitis in other studies, generally these
previous studies have not evaluated combinations of biomarkers
representing the various disease processes that occur in
periodontitis, nor have they included patients with gingivitis to
elucidate the effect of gingival inflammation on these analytes.
This cross-sectional study enabled a “head-to-head” comparison
of these salivary analytes in destructive (periodontitis) and nondestructive reversible (gingivitis) gingival inflammation. Thus,
we can conclude from these studies that select biomarkers,
particularly in combination provide enhanced sensitivity and
specificity for identification of periodontitis in the population.
Also, of important note, as can be seen in the salivary
analyte distribution graphs, there was a subset of gingivitis
patients and even a few healthy subjects that demonstrated
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